BOI 📈 Boiron SA - Overview
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000061129
BOI: Homeopathic Medicines, Medical Devices, Dietary Supplements, Cosmetics, Phytotherapy
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France. Web URL: https://www.boiron.fr
Additional Sources for BOI Stock
BOI Stock Overview
| Market Cap in USD | 485m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
BOI Stock Ratings
| Growth 5y | 13.6% |
| Fundamental | 51.6% |
| Dividend | 63.9% |
| Rel. Strength Industry | -4612 |
| Analysts | - |
| Fair Price Momentum | 22.96 EUR |
| Fair Price DCF | 66.32 EUR |
BOI Dividends
| Dividend Yield 12m | 5.04% |
| Yield on Cost 5y | 5.42% |
| Annual Growth 5y | 5.15% |
| Payout Consistency | 90.8% |
BOI Growth Ratios
| Growth Correlation 3m | -83% |
| Growth Correlation 12m | -76% |
| Growth Correlation 5y | 72.6% |
| CAGR 5y | 1.43% |
| CAGR/Mean DD 5y | 0.11 |
| Sharpe Ratio 12m | -1.42 |
| Alpha | -41.38 |
| Beta | 0.13 |
| Volatility | 30.78% |
| Current Volume | 0.5k |
| Average Volume 20d | 2.2k |
What is the price of BOI stocks?
As of January 02, 2025, the stock is trading at EUR 26.80 with a total of 463 shares traded.
Over the past week, the price has changed by +0.37%, over one month by +1.32%, over three months by -18.17% and over the past year by -31.68%.
As of January 02, 2025, the stock is trading at EUR 26.80 with a total of 463 shares traded.
Over the past week, the price has changed by +0.37%, over one month by +1.32%, over three months by -18.17% and over the past year by -31.68%.
Is Boiron SA a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Boiron SA (PA:BOI) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 51.57 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BOI as of January 2025 is 22.96. This means that BOI is currently overvalued and has a potential downside of -14.33%.
Partly, yes. Based on ValueRay Fundamental Analyses, Boiron SA (PA:BOI) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 51.57 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BOI as of January 2025 is 22.96. This means that BOI is currently overvalued and has a potential downside of -14.33%.
Is BOI a buy, sell or hold?
Boiron SA has no consensus analysts rating.
Boiron SA has no consensus analysts rating.
What are the forecast for BOI stock price target?
According to ValueRays Forecast Model, BOI Boiron SA will be worth about 24.8 in January 2026. The stock is currently trading at 26.80. This means that the stock has a potential downside of -7.31%.
According to ValueRays Forecast Model, BOI Boiron SA will be worth about 24.8 in January 2026. The stock is currently trading at 26.80. This means that the stock has a potential downside of -7.31%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 33.3 | 24.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.8 | -7.3% |